Octagon Therapeutics Receives Agilent Golden Ticket

Lewis Botcherby

The Column, The Column-05-06-2021, Volume 17, Issue 05
Pages: 10

Agilent Technologies Inc. has announced that Octagon Therapeutics have been awarded an Agilent Golden Ticket at LabCentral.

Agilent Technologies Inc. (California, USA) has announced that Octagon Therapeutics (Massachusetts, USA) have been awarded an Agilent Golden Ticket at LabCentral. The Golden Ticket provides funding for one scientist’s laboratory bench space for a year, including the benefit of LabCentral’s shared infrastructure and services.

Octagon’s mission is to discover and develop better treatments for autoimmune disease. The immune cells that drive autoimmune disease are genetically identical to healthy immune cells, but have become pathologically activated in specific ways. Octagon’s platform enables the identification of the hallmarks of immune dysregulation, allowing the precise treatment of autoimmune conditions without damaging healthy immune functioning. The ability to treat an autoimmune disease’s underlying drivers without suppressing the immune system is necessary to prevent secondary complications.

“We are thrilled to have won the Agilent Golden Ticket,” said Isaac Stoner, president and chief executive officer of Octagon Therapeutics. “Octagon has identified important new biology related to the underlying causes of autoimmune disease. The analytical chemistry expertise and instrumentation that Agilent has provided to LabCentral will be critically important as we turn these insights into new medicines, and the vibrant LabCentral community will help to shape our company culture as we grow.”

“It’s great to see Octagon awarded with Agilent’s 2021 Golden Ticket. We are excited about the potential of their autoimmune‑therapeutics platform,” said Johannes Fruehauf, co‑founder and president of LabCentral.

For more information, please visit: www.agilent.com

download issueDownload Issue : The Column-05-06-2021